Document:

aimt-ex103_407.htm

Exhibit 10.3

 

Aimmune therapeutics, inc.

 

Non-Employee DIRECTOR COMPENSATION PROGRAM

 

Non-employee members of the board of directors (the “Board”) of Aimmune Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which is being adopted pursuant to the Board’s resolutions on July 24, 2015, as subsequently revised by the Compensation Committee of the Board on May 10, 2017, May 23, 2018 and May 22, 2019.  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time, without advance notice, in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  This Program, as revised herein, shall be effective as of May 22, 2019 (the “Effective Date”).

1.Cash Compensation.  

(a)Annual Retainers.  Each Non-Employee Director shall be eligible to receive an annual retainer of $40,000 for service on the Board.  

(b)Additional Annual Retainers.  In addition, a Non-Employee Director shall receive the following annual retainers:

(i)Chairman of the Board.  A Non-Employee Director serving as Chairman of the Board shall receive an additional annual retainer of $30,000 for such service.

(ii)Audit Committee.   A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service.  A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $10,000 for such service.

(iii)Compensation Committee.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.

(iv) Nominating and Corporate Governance Committee.   A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.

(iv) Research and Development Committee.   A Non-Employee Director serving as Chairperson of the Research and Development Committee shall receive an additional annual 

 

 

retainer of $11,000 for such service.  A Non-Employee Director serving as a member of the Research and Development Committee (other than the Chairperson) shall receive an additional annual retainer of $5,500 for such service.

(c)Payment of Retainers.  The annual retainers described in Sections 1(a) and 1(b) shall b

e earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth (15th) day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.

 

2.Equity Compensation.  Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2015 Equity Incentive Award Plan, as amended from time to time, or any other applicable Company equity incentive plan then-maintained by the Company (in any case, the “Equity Plan”) and shall be evidenced by the execution and delivery of award agreements in substantially the forms approved by the Board from time to time.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.  

	

	
(a)Initial Awards.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall automatically be granted, on the date of such initial election or appointment, an option (an “Initial Option”) to purchase shares of the Company’s common stock (“Shares”) having a grant date fair value of $225,000, calculated based on the 30-day average closing price of the Shares as of the trading day immediately preceding the date of grant and using assumptions published in the Company’s most recent periodic report as of the date of grant and a number of restricted stock units calculated by dividing $225,000 by the 30-day average closing price of a Share as of the trading day immediately preceding the date of grant (the “Initial RSUs” and, together with the Initial Option, the “Initial Award”).  No Non-Employee Director shall be granted more than one Initial Award.  

	

	
(b)Subsequent Awards.  A Non-Employee Director who (i) has been serving on the Board immediately prior to any annual meeting of the Company’s stockholders after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted, on the date of such annual meeting, an option (a “Subsequent Option”) to purchase Shares having a grant date fair value of $132,500, calculated based on the 30-day average closing price of the Shares as of the trading day immediately preceding the date of grant and using assumptions published in the Company’s most recent periodic report as of the date of grant, and that number of RSUs calculated by dividing $132,500 by the 30-day average closing price of a share as of the trading day immediately preceding the date of grant (“Subsequent RSUs” and, together with a Subsequent Option, a “Subsequent Award”).

 

(c)Termination of Service of Employee Directors.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.  

2

 

 

 

 

(d)Terms of Awards Granted to Non-Employee Directors

	

	
(i)Exercise Price.  The per Share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a Share on the date the option is granted.  

	

	
(ii)Vesting.  Subject to Section 2(d)(iii) below, each Initial Option shall vest and become exercisable in thirty-six (36) substantially equal installments on each monthly anniversary of the date of grant and each award of Initial RSUs shall vest in respect of 1/3rd of the total number of RSUs subject to the grant on each of the first three anniversaries of the date of grant, in each case, subject to the Non-Employee Director continuing to provide services to the Company through each such vesting date.  Subject to Section 2(d)(iii) below, each Subsequent Award shall vest and, in the case of a Subsequent Option, become exercisable in full on the earlier of the one year anniversary of the date of grant and the next annual meeting of the Company’s stockholders after the grant date, subject to the Non-Employee Director continuing to provide services to the Company through such vesting date.  

	
 
	
(iii)
	
Accelerated Vesting.  

(A) Termination Due to Death or Disability.  In the event that any Non-Employee Director incurs a Termination of Service (as defined in the Equity Plan) due to such Non-Employee Director’s death or Disability (as defined below), each of such Non-Employee Director’s Initial Award and Subsequent Award(s), along with any other stock options or other equity-based awards held by such Non-Employee Director, shall vest and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto upon such Termination of Service.  For purposes of this Program, “Disability” shall mean a permanent and total disability within the meaning of Section 22(e)(3) of the Internal Revenue Code of 1986, as amended.  

(B)Change in Control.  In the event that a Change in Control (as defined in the Equity Plan) occurs, each Initial Award and Subsequent Award, along with any other stock options or other equity-based awards held by any Non-Employee Director, shall vest and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto as of immediately prior to such Change in Control.

(iv)Term.  The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted. 

	
3.
	
Reimbursements.  The Company shall reimburse each Non-Employee Director for all reasonable, documented, out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company’s applicable expense reimbursement policies and procedures as in effect from time to time. 

* * * * *

3Exhibit

Exhibit 10.2
EMPLOYMENT APPORTIONMENT AGREEMENT
 This Employment Apportionment Agreement (this “Agreement”) is made and entered into by and among BeiGene (Beijing) Co., Limited (the “Company”), BeiGene Guangzhou Biologics Manufacturing Co., Ltd. (the “GZ Co.”), and Dr. Wu Xiaobin (the “Executive”), on March 1, 2020 (the “Effective Date”).  Capitalized terms used but not defined in this Agreement shall have the meanings assigned to them in the Executive Employment Agreement entered into by and between the Company and the Executive, effective as of April 30, 2018 (the “Employment Agreement”). 
WHEREAS, the Company entered into the Employment Agreement with the Executive effective as of April 30, 2018; and 
WHEREAS, the GZ Co., an affiliate of the Company and the Executive wish to establish an employment relationship for the Executive to provide certain service for the GZ Co. and the Company wishes to consent to the establishment of the additional employment relationship between the GZ Co. and the Executive. 
NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, terms, provisions and conditions set forth in this Agreement, the parties hereby agree: 
1. Employment. Subject to the terms and conditions set forth in this Agreement, the Executive shall be employed by the GZ Co. to undertake certain work. The Company agrees and consents to the additional employment relationship between the GZ Co. and the Executive.  This Agreement constitutes an employment agreement between the GZ Co. and the Executive. 
2. Term. The Term of this Agreement shall start from the Effective Date of this Agreement and expire on the termination date of the Employment Agreement, subject to the Executive’s timely obtaining and maintenance of requisite visa, work permit and/or residence permit (as applicable) under the relevant PRC laws. 
3. Capacity and Performance. Subject to the terms and conditions of Section 3 of the Employment Agreement as well as the Article of Association of the GZ Co., during the Term, the Executive shall serve the GZ Co. as the Legal Representative and Chairman of the Board of Directors, and shall report to the Board of Directors of the GZ Co.   
4. Compensation and Benefits. Subject to the terms and conditions of the Employment Agreement, as compensation for all services performed by the Executive for the GZ Co. during the Term and subject to the Executive’s performance of his duties and obligations to the GZ Co., pursuant to this Agreement, the GZ Co. shall provide the Executive with compensation and benefits pursuant to the following arrangement: 
		
	a)
	Base Salary. During the Term, the payment of the Base Salary shall be allocated between the Company and the GZ Co. pursuant to this Agreement.  In 2020, the Company shall be responsible for 70% of the Base Salary and the GZ Co. shall be responsible for 30% of the Base Salary.  To the extent the GZ Co. does not make timely payment of its portion of the Base Salary, the Company shall be obligated to make such payment and the GZ Co. agrees to reimburse the Company any such payment made by the Company on behalf of the GZ Co. as soon as reasonably practicable.  Within the first 30 days of each following calendar year, the Company and the GZ Co. shall true up each other based on the final allocation of compensation expenses between the Company and the GZ Co. in the past calendar year and shall assess and re-allocate the payment responsibility of the Base Salary for the current year as necessary.  The Executive agrees to such payment allocation arrangement as agreed by the Company and the GZ Co.   

		
	b)  
	Other Compensation and Benefits. During the Term, the Executive shall be entitled to participate in or receive compensation or benefits provided by the GZ Co. as set forth in Sections 4 and 5 of the Employment Agreement, except to the extent any such benefit is in a category of benefit otherwise provided to the Executive by the Company or another affiliate of the Company. 

c)  Business Expenses. During the Term, the GZ Co. shall pay (or promptly reimburse the Executive) for documented, out-of-pocket expenses reasonably incurred by the Executive in the course of performing his duties and responsibilities hereunder, which are consistent with the GZ Co.’s policies in effect from time to time with respect to business expenses, subject to the GZ Co.’s requirements with respect to reporting of such expenses. 
5. Termination of Employment. This Agreement and the Executive’s employment relationship hereunder shall terminate immediately upon any of the following circumstances occur: (i) the expiration of the Term (i.e. upon termination of the Executive’s employment under the Employment Agreement); or (ii) any visa, work permit or other certificate or document 

1

required for the Executive under the applicable PRC laws is expired, terminated or revoked.  Furthermore, the GZ Co. shall have the right to shorten the Term of the employment relationship hereunder or terminate this Agreement in advance, with or without reason, provided that the GZ Co. informs the Executive in writing 60 days in advance. 
6. Severance Payments and Other Matters Related to Separation under the Employment Agreement. As soon as reasonably practicable after the payment of the Severance Benefits to the Executive by the Company pursuant to the Employment Agreement, the GZ Co. shall reimburse the Company of its portion of such payment calculated based on the allocation determined pursuant to Section 4 of this Agreement.  For avoidance of doubt, the portion of the Severance Benefits calculated based on the allocation determined pursuant to Section 4 of this Agreement shall constitute the severance payments that the Executive may be entitled to for termination of this Agreement or the employment relationship hereunder.  Furthermore, the Company shall not require the GZ Co. to bear any amount other than its portion as agreed under this Agreement. 
7. Withholding. All payments made by the GZ Co. under this Agreement shall be reduced by any tax or other amounts required to be withheld by the GZ Co. under applicable law.  In the event the Executive shall participate in the PRC social insurance scheme according to the relevant PRC laws and local regulations, the GZ Co. will withhold and deduct the individual’s part of social insurance contributions from the portion of Base Salary payable by the GZ Co. pursuant to law. 
8. Conflicting Agreements. The Executive hereby represents and warrants that the execution of this Agreement and the performance of his obligations hereunder will not breach or be in conflict with any other agreement to which the Executive is a party or is bound and that the Executive is not now subject to any covenants against competition or similar covenants or any court order or other legal obligation that would affect the performance of his obligations hereunder. The Executive will not disclose to or use on behalf of the GZ Co. any proprietary information of a third party without such party’s consent. 
9. Non-disparagement. Executive agrees that he will not, directly or indirectly, individually or in concert with others, engage in any conduct or make any statement that is likely to have the effect of undermining or disparaging the reputation of the GZ Co., or its good will, products, or business opportunities, or that is likely to have the effect of undermining or disparaging the reputation of any officer, director, agent, representative or employee, past or present, of the GZ Co.  The GZ Co. agrees that, except for circumstances relating to a termination of Executive’s employment by the Company for Cause, its officers, directors and senior management shall not directly or indirectly, individually or in concert with others, engage in any conduct or make any statement that is likely to have the effect of undermining or disparaging the reputation of Executive. 
10. Survival. Provisions of this Agreement shall survive any termination if so provided herein or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation the obligations of the Executive under Sections 8 and 9 hereof, and obligations of the GZ Co. under Sections 4, 5, 6 and 9. 
11. Severability. If any covenants or such other provisions of this Agreement are found to be invalid or unenforceable by a final determination of a court of competent jurisdiction, (a) the remaining terms and provisions hereof shall be unimpaired, and (b) the invalid or unenforceable term or provision hereof shall be deemed replaced by a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision hereof. 
12. Waiver and Amendments. Any waiver, alteration, amendment, or modification of any of the terms of this Agreement shall be valid only if made in writing and signed by each of the parties hereto.  No waiver by either of the parties hereto of their rights hereunder shall be deemed to constitute a waiver with respect to any subsequent occurrences or transactions hereunder unless such waiver specifically states that it is to be construed as a continuing waiver. 
13. Notices. Every notice or other communication relating to this Agreement shall be in writing, and shall be mailed to or delivered to the party for whom or which it is intended at such address as may from time to time be designated by it in a notice mailed or delivered to the other party as herein provided; provided, that unless and until some other address be so designated, all notices and communications by the Executive to the GZ Co. or the Company shall be mailed or delivered to the GZ Co. or the Company at its principal executive office, and all notices and communications by the GZ Co. or the Company to the Executive may be given to the Executive personally or may be mailed to the Executive at the Executive’s last known address, as reflected in the GZ Co. or the Company’s records. Any notice so addressed shall be deemed to be given or received (a) if delivered by hand, on the date of such delivery, (b) if mailed by courier or by overnight mail, on the first business day following the date of such mailing, and (c) if mailed by registered or certified mail, on the third business day after the date of such mailing. 
14. Entire Agreement. This Agreement constitutes the entire understanding and agreement of the parties hereto regarding the employment of the Executive by the GZ Co.  This Agreement and the Employment Agreement supersede all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the parties relating to the subject matter of this Agreement and the Employment Agreement.  

2

15. Section Headings. The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part thereof or affect the meaning or interpretation of this Agreement or of any term or provision hereof. 
16. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.  The execution of this Agreement may be by actual or facsimile signature. 
17. Governing Law and Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the PRC, without regard to conflicts of laws principles thereof.  The parties hereby consent to the jurisdiction of any court in Beijing, China.  Accordingly, with respect to any such court action, the Executive hereby (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.
[Signature Page to Follow]

3

 
IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Company and the GZ Co., by their duly authorized representatives, and by the Executive, as of the date first above written.
 
 
	
				
	EXECUTIVE
	 
	BEIGENE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.

	 
	 
	(Chop)

	 
	 
	 

	/s/ Wu Xiaobin
	 
	By:
	/s/ Jonathan Liu

	Dr. Wu Xiaobin
	 
	Name: 
Its:
	Jonathan Liu
General Manager

	 
	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	BEIGENE (BEIJING) CO., LIMITED

	 
	 
	(Chop)

	 
	 
	 

	 
	 
	By:
	/s/ Scott A. Samuels

	 
	 
	Name:
	Scott A. Samuels

	 
	 
	Its:
	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]